{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:38:28Z","timestamp":1793353108985,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84077-w","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T19:20:54Z","timestamp":1735845654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Rachael A.","family":"Potter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida H.","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Haegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hollenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon R.","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Palatinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84077_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6 (2010).","journal-title":"Lancet Neurol."},{"key":"84077_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli, S. et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J. Rare Dis. 15, 141. https:\/\/doi.org\/10.1186\/s13023-020-01430-8 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"84077_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982 (2013).","journal-title":"Ann. Neurol."},{"key":"84077_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-u","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery, A. E. Population frequencies of inherited neuromuscular diseases\u2013a world survey. Neuromuscul. Disord. 1, 19\u201329. https:\/\/doi.org\/10.1016\/0960-8966(91)90039-u (1991).","journal-title":"Neuromuscul. Disord."},{"key":"84077_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/jnd-210640","volume":"8","author":"G Norcia","year":"2021","unstructured":"Norcia, G. et al. Early gross motor milestones in Duchenne muscular dystrophy. J. Neuromuscul. Dis. 8, 453\u2013456. https:\/\/doi.org\/10.3233\/jnd-210640 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"84077_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers 7, 13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"84077_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"D Asher","year":"2020","unstructured":"Asher, D. et al. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin. Biol. Ther. 20, 263\u2013274. https:\/\/doi.org\/10.1080\/14712598.2020.1725469 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"84077_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-60327-248-3_13","volume":"434","author":"C Zheng","year":"2008","unstructured":"Zheng, C. & Baum, B. J. Evaluation of promoters for use in tissue-specific gene delivery. Methods Mol. Biol. 434, 205\u2013219. https:\/\/doi.org\/10.1007\/978-1-60327-248-3_13 (2008).","journal-title":"Methods Mol. Biol."},{"key":"84077_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"J Mendell","year":"2020","unstructured":"Mendell, J. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 77, 1121\u20131131. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484 (2020).","journal-title":"JAMA Neurol."},{"key":"84077_CR10","unstructured":"US Food and Drug Administration. ELEVIDYS\u2122 (delandistrogene moxeparvovec-rokl) Highlights of prescribing information. https:\/\/www.fda.gov\/media\/169679\/download  (2023). Accessed Dec 2024."},{"key":"84077_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell, J. R. et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve 69, 93\u201398. https:\/\/doi.org\/10.1002\/mus.27955 (2024).","journal-title":"Muscle Nerve"},{"key":"84077_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","volume":"153","author":"JR Mendell","year":"2024","unstructured":"Mendell, J. R. et al. Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr. Neurol. 153, 11\u201318. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.01.003 (2024).","journal-title":"Pediatr. Neurol."},{"key":"84077_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26755","author":"CM Zaidman","year":"2023","unstructured":"Zaidman, C. M. et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from Study SRP-9001-103 (ENDEAVOR). Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.26755 (2023).","journal-title":"Ann. Neurol."},{"key":"84077_CR14","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell, J. R. et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front. Cell. Dev. Biol. 11, 1167762. https:\/\/doi.org\/10.3389\/fcell.2023.1167762 (2023).","journal-title":"Front. Cell. Dev. Biol."},{"key":"84077_CR15","unstructured":"Goedeker NL et al. Management of patients following investigational delandistrogene moxeparvovec gene therapy for Duchenne muscular dystrophy: Delphi panel consensus considerations based on clinical trial experience. Presented at the 2023 American Society of Gene and Cell Therapy Annual Meeting, Los Angeles, CA, USA. https:\/\/investorrelations.sarepta.com\/static-files\/ad325995-7c11-4504-b37f-1fbbba67f383. (2023). Accessed Dec 2024."},{"key":"84077_CR16","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl, H. C. J. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 13, 975803. https:\/\/doi.org\/10.3389\/fimmu.2022.975803 (2022).","journal-title":"Front Immunol."},{"key":"84077_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/17512433.2014.852065","volume":"7","author":"F Salmon","year":"2014","unstructured":"Salmon, F., Grosios, K. & Petry, H. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera\u00ae). Expert Rev. Clin. Pharmacol. 7, 53\u201365. https:\/\/doi.org\/10.1586\/17512433.2014.852065 (2014).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"84077_CR18","unstructured":"Khan, S. et al. T-cell response to micro-dystrophin in a patient treated with delandistrogene moxeparvovec gene therapy: a case of immune-mediated myositis. Presented at the 28th International Annual Congress of the World Muscle Society (WMS 2023). Charleston, SC, USA, 2023. https:\/\/investorrelations.sarepta.com\/static-files\/51d79e1a-7ef7-46c6-93e3-c63b7be11238. (2023). Accessed Dec 2024."},{"key":"84077_CR19","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG Bonnemann","year":"2023","unstructured":"Bonnemann, C. G. et al. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 388, 2294\u20132296. https:\/\/doi.org\/10.1056\/NEJMc2212912 (2023).","journal-title":"N. Engl. J. Med."},{"key":"84077_CR20","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.1007\/s00415-024-12431-z","volume":"271","author":"ST Iannaccone","year":"2024","unstructured":"Iannaccone, S. T. et al. Immune-mediated myositis following gene therapy for Duchenne muscular dystrophy: a case report. J. Neurol. 271, 5659\u20135664. https:\/\/doi.org\/10.1007\/s00415-024-12431-z (2024).","journal-title":"J. Neurol."},{"key":"84077_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fimmu.2011.00048","volume":"2","author":"PJ van den Elsen","year":"2011","unstructured":"van den Elsen, P. J. Expression regulation of major histocompatibility complex class I and class II encoding genes. Front. Immunol. 2, 48. https:\/\/doi.org\/10.3389\/fimmu.2011.00048 (2011).","journal-title":"Front. Immunol."},{"key":"84077_CR22","doi-asserted-by":"publisher","first-page":"eadj6367","DOI":"10.1126\/sciadv.adj6367","volume":"9","author":"JB Nilsson","year":"2023","unstructured":"Nilsson, J. B. et al. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning. Sci. Adv. 9, eadj6367. https:\/\/doi.org\/10.1126\/sciadv.adj6367 (2023).","journal-title":"Sci. Adv."},{"key":"84077_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res.\u00a048, W449\u2013W454. https:\/\/doi.org\/10.1093\/nar\/gkaa379 (2020).","journal-title":"Nucleic Acids Res."},{"key":"84077_CR24","first-page":"158","volume":"56","author":"AV Winnard","year":"1995","unstructured":"Winnard, A. V., Mendell, J. R., Prior, T. W., Florence, J. & Burghes, A. H. Frameshift deletions of exons 3\u20137 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production. Am. J. Hum. Genet. 56, 158\u2013166 (1995).","journal-title":"Am. J. Hum. Genet."},{"key":"84077_CR25","first-page":"562","volume":"51","author":"SB Gangopadhyay","year":"1992","unstructured":"Gangopadhyay, S. B. et al. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am. J. Hum. Genet. 51, 562\u2013570 (1992).","journal-title":"Am. J. Hum. Genet."},{"key":"84077_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/978-981-15-0602-4_28","volume":"1206","author":"YX Wu","year":"2019","unstructured":"Wu, Y. X., Jin, S. H. & Cui, J. Autophagy and immune tolerance. Adv. Exp. Med. Biol. 1206, 635\u2013665. https:\/\/doi.org\/10.1007\/978-981-15-0602-4_28 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"84077_CR27","unstructured":"ClinicalTrials.gov. NCT04281485: a phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy. https:\/\/clinicaltrials.gov\/study\/NCT04281485 (2024). Accessed Dec 2024."},{"key":"84077_CR28","unstructured":"Clinicaltrialsregister.eu. 2020-002093-27: microdystrophin (GNT0004) gene therapy clinical trial in Duchenne muscular dystrophy. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002093-27\/FR (2020). Accessed Dec 2024."},{"key":"84077_CR29","unstructured":"Bonnemann, C. et al. A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD; Poster 44. Presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Dallas, USA. https:\/\/www.mdaconference.org\/abstract-library\/a-collaborative-analysis-by-clinical-trial-sponsors-and-academic-experts-of-anti-transgene-saes-in-studies-of-gene-therapy-for-dmd\/ (2023). Accessed Dec 2024."},{"key":"84077_CR30","unstructured":"ClinicalTrials.gov. NCT05096221: a gene transfer therapy study to evaluate the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in participants with Duchenne muscular dystrophy (DMD) (EMBARK). https:\/\/clinicaltrials.gov\/study\/NCT05096221 (2022). Accessed Dec 2024."},{"key":"84077_CR31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437. https:\/\/doi.org\/10.1056\/NEJMoa1000228 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84077-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:13:50Z","timestamp":1735848830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84077-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84077"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84077-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.A.P.,\u00a0I.H.M., S.K., D.R.A., E.P., D.A.G., and S.M. are employees of Sarepta Therapeutics and may have stock options. H.H., A.H., G.S., and C.W. are employees of F. Hoffmann-La Roche Ltd and may have stock options. A.P.M. is an employee of Roche Products Ltd and may have stock options. S.T.I. receives research support from industry (Elpida, Novartis, Biogen, Sarepta Therapeutics, PTC Therapeutics, Scholar Rock, FibroGen, RegenxBio, and ReveraGen) and the Department of Defense W81XWH2010293, Parent Project Muscular Dystrophy, and Cure SMA. She has served on medical advisory boards for Novartis, Biogen, Genentech, and Sarepta Therapeutics. She receives partial salary support from the following grants: National Institutes of Health Wellstone Muscular Dystrophy Center P50HD087351, NeuroNEXT U24NS107176, and the Muscular Dystrophy Association. C.M.Z. receives research support from Biogen and Novartis and has served on an advisory board for Sarepta Therapeutics. L.R.R.K. is an employee of Sarepta Therapeutics and may have stock options and is a co-inventor of AAVrh74.MHCK7.SRP-9001-dys technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}